Thymosin alpha 1 gets mentioned in the same breath as TB-500 often enough that the two get mixed up, even though they are studied for completely different reasons. This guide explains what thymosin alpha 1 actually is, clears up the confusion with TB-500, and walks through what immune research has found so far.
What Is Thymosin Alpha-1?
Thymosin alpha-1 is a short peptide, a chain of just 28 amino acids, that the body naturally produces as a piece cut from a longer protein called prothymosin alpha. It was first studied in the 1960s and 1970s by researchers investigating the thymus, the small organ behind the breastbone that trains immune cells early in life, which is where the “thymosin” name comes from, even though the protein it comes from turns up in tissue well beyond the thymus itself.
The lab-made version used in research and, in some countries, in medicine, is called thymalfasin, sold under the brand name Zadaxin where it is approved. In the United States, thymosin alpha-1 is not broadly approved by the FDA. Here, it is treated strictly as a laboratory research compound rather than an approved medicine.
Is Thymosin Alpha-1 the Same as TB-500?
No. Despite the similar-sounding name, thymosin alpha-1 and TB-500 are structurally and genetically unrelated compounds that just happen to share the word “thymosin.”
- TB-500 comes from a different family entirely. TB-500 is the lab-made version of thymosin beta-4, a peptide first studied for wound healing. Researchers actually discovered its most talked-about effect by accident, while studying wound repair in mice, when they noticed it also triggered faster hair growth.
- The two are grouped by an old lab technique, not by function. Thymosins were originally sorted into alpha, beta, and gamma groups based on how they moved in an electrical field during lab testing, not because they do similar things in the body. Alpha and beta thymosins are, in the researchers’ own words, structurally and genetically unrelated.
- The simplest way to remember the difference: thymosin alpha-1 is studied for immune signaling, while TB-500 is studied for tissue repair. They are frequently discussed side by side in peptide research because of the shared name, not because they do the same job.
How Does It Work?
Thymosin alpha-1 is studied for how it fine-tunes parts of the immune system rather than broadly boosting it. Research describes it attaching to two “docking points” found on certain immune cells, called toll-like receptor 2 and toll-like receptor 9. These docking points work like sensors that immune cells use to detect a threat and decide how strongly to respond.
By interacting with those sensors, thymosin alpha-1 is studied for helping immune cells called T cells and dendritic cells coordinate a more targeted response, the kind of immune activity aimed at cells that are infected or abnormal, rather than a general, body-wide immune reaction. That targeted, coordinating role is why researchers describe it as an immune modulator rather than a blanket immune booster.
Benefits of Thymosin Alpha-1?
Most of what is documented about thymosin alpha-1 comes from international clinical use and research settings outside the United States, where it has a longer approval history than it does domestically.
- Approved in some countries for hepatitis B and C. Alongside standard treatment, thymosin alpha-1 is approved in a number of countries as a way to support the immune system’s response to these chronic viral infections.
- Studied in serious infection and inflammation research. Research has examined thymosin alpha-1 in the context of sepsis, a dangerous body-wide reaction to infection, as well as in tuberculosis research, where a better-coordinated immune response is the goal.
- Studied as an add-on in certain cancer research. Some research has looked at thymosin alpha-1 alongside other treatments in specific cancers, examining whether supporting immune coordination improves outcomes.
- Examined during the COVID-19 pandemic. Researchers studied thymosin alpha-1 as a possible immune-support option during COVID-19, though results across different studies have been mixed rather than conclusive.
- Still a research-only compound in the U.S. None of this changes its regulatory status domestically. Thymosin alpha-1 is not FDA-approved here and is sold strictly for laboratory research, not as a treatment.
Handling and Storage
Thymosin alpha-1 research material follows the same general handling rules used across peptide research.
- It typically arrives as a freeze-dried powder. Like most research peptides, thymosin alpha-1 is shipped as a lyophilized powder in a sealed vial, which needs to be reconstituted, meaning mixed with a liquid, before it can be measured out.
- Bacteriostatic water is the standard mixing liquid. This is sterile water with a small amount of preservative added, usually added slowly down the side of the vial and mixed with a gentle swirl rather than a shake.
- Concentration is a simple calculation. Concentration (mg/mL) equals the vial’s labeled strength divided by however much water is added. Our peptide reconstitution calculator runs this calculation automatically.
- Store cold and dark, both before and after mixing. Unreconstituted powder should stay refrigerated or frozen and out of direct light. Once mixed, the solution should be refrigerated and used within the window stated in the supplier’s documentation, and repeated freeze-thaw cycles should be avoided.
This content is provided for Research Use Only (RUO). The compounds discussed are not drugs, dietary supplements, foods, or cosmetics, and are not intended for human or animal consumption, diagnostic use, or therapeutic use of any kind. They have not been evaluated by the FDA for safety or efficacy in humans. Any research use must be conducted by qualified professionals in a controlled laboratory environment, in accordance with all applicable institutional, local, and federal regulations.
FAQ
What is thymosin alpha-1?
Thymosin alpha-1 is a 28-amino-acid peptide naturally produced in the body and studied for its role in regulating immune responses. Its lab-made version, thymalfasin, is approved in some countries for conditions like hepatitis B and C.
Is thymosin alpha-1 the same as TB-500?
No. They are structurally and genetically unrelated peptides that happen to share the “thymosin” name. Thymosin alpha-1 is studied for immune signaling, while TB-500 is studied for tissue repair.
Is thymosin alpha-1 approved by the FDA?
It is not broadly approved in the United States. It is approved in some other countries for specific conditions, but in the U.S. it is sold strictly for laboratory research use.
What has research examined thymosin alpha-1 for?
Research and international clinical use have examined it in connection with hepatitis B and C, sepsis, tuberculosis, certain cancers as an add-on treatment, and, more recently, COVID-19, with mixed results in that last area.
Sources
- Wikipedia. Thymalfasin, its origin from prothymosin alpha, mechanism, and international approval status.
- Wikipedia. Thymosin, the discovery of thymosins and the distinction between the alpha and beta thymosin families.
- Innerbody Research. Thymosin alpha-1, background on its immune-signaling mechanism and researched applications.
Thymosin alpha-1’s focus on immune signaling places it alongside other immune and gut-focused research on this site, including the KPV peptide and what the research shows about gut and skin inflammation, even though the two work through different mechanisms.
